Novo Nordisk unveiled a strategy this week aimed at revitalizing growth, planning to diversify its product pipeline to drive expansion after the patents for its blockbuster drugs Wegovy and Ozempic expire in the early 2030s. However, Wall Street analysts are skeptical of this roadmap, deeming its growth targets merely on par with industry averages and noting a lack of clarity in its near-term turnaround plans. Meanwhile, Eli Lilly continues to expand its lead in the GLP-1 drug market, particularly dominating the oral weight-loss drug Foundayo and the Medicare obesity drug market.